관리-도구

편집 파일: 1618779889.M679471P27345.server.saraya-global.com,S=79742,W=80465:2,

Envelope-to: info@worldwide.saraya.com
Delivery-date: Mon, 19 Apr 2021 05:04:49 +0800
Date: Sun, 18 Apr 2021 23:03:32 +0200
To: info@worldwide.saraya.com
From: PMC Acquisitions + Licensing <info@licensing4pharma.de>
Reply-to: PMC Acquisitions + Licensing <info@licensing4pharma.de>
Message-ID: <cc63032ee40edd6fa81a3cd738d16e60@www.licensing4pharma.com>
MIME-Version: 1.0
Content-Type: multipart/related;
	type="text/html";
	boundary="b1_cc63032ee40edd6fa81a3cd738d16e60"
Subject:  ***SPAM***  PMC-Newsletter - Acquisition & Partnering Opportunities / Pharma, Healthcare, Chemicals & Consumer Goods

--b1_cc63032ee40edd6fa81a3cd738d16e60
Content-Type: multipart/alternative;
	boundary="b2_cc63032ee40edd6fa81a3cd738d16e60"

--b2_cc63032ee40edd6fa81a3cd738d16e60
Content-Type: text/plain; charset = "iso-8859-1"
Content-Transfer-Encoding: 8bit

To view the message, please use an HTML compatible email viewer!

--b2_cc63032ee40edd6fa81a3cd738d16e60
Content-Type: text/html; charset = "iso-8859-1"
Content-Transfer-Encoding: 8bit

<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN">
<html>
<head><META http-equiv="Content-Type" content="text/html;charset=iso-8859-1">
<title>Unbenanntes Dokument</title>
</head>
<body>
	<div style="font-family: Arial, Helvetica, sans-serif;font-size:0.9em">
		<p><a href="http://www.licensing4pharma.com/redirect.php?url=YmM5NzE="><img alt="Logo" border="0" src="http://www.licensing4pharma.com/pmcfiles/pmc_mail_logo16.jpg?g=YmM5NzE=&amp;z=15" /></a></p>
			<p style="font-size:0.6em;"><a href="http://www.licensing4pharma.com/german_nl.php?url=YmM5NzE=">If you prefer to receive this newsletter in German, please click here!</a></p>
<table style="font-family:verdana;" border="0">
<tr><td width="70%"><h2 style="color:blue;">PMC-Newsletter - 15 / 2021</h2></td>
<td></td></tr>
</table> 
<h3>Business opportunities in Pharma, Healthcare, Chemicals and Consumer Goods </h3>
<p><a href="https://www.licensing4pharma.com/index.php?option=com_wrapper&view=wrapper&Itemid=177&lang=en"><img src="cid:b384c0cc6a789604b770c2c5a9101600" width="800" height="90" border="0" title="Click here to tailor your Individual Newsletter"></a></p>

<span style='font-size:0.8em;text-decoration:underline;'>Please forward to:</span><br /><span style='font-size:0.8em'>CEO, Managing Director<br/>
CFO, Director Finance</span><p>&nbsp;</p>

<span style="font-size:10pt"><p>Dear Madam, Dear Sir,</p>

<p></p>

<p>Below please find a random selection of companies, brands and licenses that we currently may offer for sale, and some target objects, which we are seeking to buy for strategic and financial investors.</p>
<p style='color:red;font-size:0.9em;'>To use the functions of this newsletter, we ask you to first <a href='http://www.licensing4pharma.com/index.php?option=com_wrapper&view=wrapper&Itemid=106&lang=en'>register for free</a> on our website (if not already done). After release of your account please log into the M&A Database with your Business eMail address and password (<a href='http://www.licensing4pharma.com/index.php?option=com_user&view=login&lang=en'>M&A Login</a>) and <span style='color:blue;'>activate the tickbox 'stay logged in'.</span></p><p>After login you may use all functions of the M&A Database by clicking on the respective embedded links in the newsletter below.</p>

<p>We support you effectively in finding suitable acquisition & partnering opportunities and in selling and out-licensing innovative assets and non-core businesses worldwide. Contact us if we may assist you with your investment and divestment projects.</p>
  <p>Many thanks and best regards from Zug in Switzerland</p>
	<p>Dr. M. Raber</p>
  </span>
	<p>&nbsp;</p>
	<hr>
	<table style="font-family:Verdana;font-size:0.9em;" border="0" cellspacing="2" cellpadding="1">
	<tr><td><a href="http://licensing4pharma.com/dashboard/dashboard_en.html"><img src="http://www.licensing4pharma.com/images/blue_button_small.gif" width="145" height="42" border="0"></a></td>
  <td><p style="font-size:10pt">Try our new <b>PMC-Dashboard</b> for easy navigation on our website.</p></td></tr>
  </table>
  <hr>
	<p>&nbsp;</p>
  <h2>Asset Sales &amp; Partnering Opportunities</h2>
          <p><img src="http://www.licensing4pharma.com/images/stories/fruit/zug2.jpg" border="0" width="800" height="210" /></p>
			    <h3><a style="color:blue;" href="http://www.licensing4pharma.com/index.php?option=com_wrapper&view=wrapper&Itemid=112&lang=en" target="_parent" title="switch to Corporate Sales List View">I. Corporate Sales</a></h3>
				  <h4 style='color:#000;'>Pharmaceutical Company / Anesthesia and Pain Treatment a.o.</h4><p style='text-align:left;font-size:10pt'>Currently, a pharmaceutical distribution company in Europe specializing in the marketing and distribution of proprietary drugs for anesthesia, pain treatment and sedation in children and adults is considering different strategic options as for example a sale of the company. The company employs approximately 20 people and has promising products in the pipeline with a sales potential in the 2-3 digit million EUR range, which are currently in the approval process. If you are interested in this opportunity, please contact us.
<p><a style='text-decoration:none;color:blue;font-size:8pt' href='http://www.licensing4pharma.com/newsletter_details.php?url=MTBmMQ==&amp;uid=YmM5NzE=&amp;z=15'><img src='http://www.licensing4pharma.com/images/button_more_blue.gif' width=41 height=24 border=0></a><span style='color:#cccccc;'>&nbsp;|&nbsp;</span><a style='font-size:8pt' href='http://www.licensing4pharma.com/pmcfiles/email_campaign.php?oid=MTBmMQ==&lang=en'><img src='http://www.licensing4pharma.com/images/button_blue_confidential.gif' width=150 height=24 border=0></a></p><hr style='border-top: 1px solid #CCCCCC; height: 1px;'><h4 style='color:#000;'>Distributor / natural Products - Germany</h4><p style='text-align:left;font-size:10pt'>Currently, a marketing and distribution enterprise in Germany is put up for sale, which specialized in marketing and the selling of natural products, food supplements, medicinal products and cosmetics. The profitable company is a fast growing company with attractive OTC products and a
turnover in the mid 2-digit million EUR range. Further information is available upon request.
<p><a style='text-decoration:none;color:blue;font-size:8pt' href='http://www.licensing4pharma.com/newsletter_details.php?url=MTEwYQ==&amp;uid=YmM5NzE=&amp;z=15'><img src='http://www.licensing4pharma.com/images/button_more_blue.gif' width=41 height=24 border=0></a><span style='color:#cccccc;'>&nbsp;|&nbsp;</span><a style='font-size:8pt' href='http://www.licensing4pharma.com/pmcfiles/email_campaign.php?oid=MTEwYQ==&lang=en'><img src='http://www.licensing4pharma.com/images/button_blue_confidential.gif' width=150 height=24 border=0></a></p><hr style='border-top: 1px solid #CCCCCC; height: 1px;'><h4 style='color:#000;'>Manufacturer and Distributor / Wound Treatments and Dermo-Cosmetics</h4><p style='text-align:left;font-size:10pt'>The company specializes in the manufacture and worldwide distribution of products for the medical-cosmetic treatment of skin lesions, wounds, burns and plastic surgery procedures to achieve an esthetically optimal result. Furthermore, cosmetics and skin care
products belong to the company s product range. The strongly growing, profitable company employs more than 130 employees worldwide and has a turnover in the mid 2-digit million EUR range. Confidential information is available upon request.
<p><a style='text-decoration:none;color:blue;font-size:8pt' href='http://www.licensing4pharma.com/newsletter_details.php?url=ZmM4&amp;uid=YmM5NzE=&amp;z=15'><img src='http://www.licensing4pharma.com/images/button_more_blue.gif' width=41 height=24 border=0></a><span style='color:#cccccc;'>&nbsp;|&nbsp;</span><a style='font-size:8pt' href='http://www.licensing4pharma.com/pmcfiles/email_campaign.php?oid=ZmM4&lang=en'><img src='http://www.licensing4pharma.com/images/button_blue_confidential.gif' width=150 height=24 border=0></a></p><hr style='border-top: 1px solid #CCCCCC; height: 1px;'><h4 style='color:#000;'>Pharmaceutical Marketing & Distribution Co. / BeNeLux</h4><p style='text-align:left;font-size:10pt'>The company employs 21 people and specializes in the marketing and distribution of niche pharmaceuticals and in vitro diagnostics in the Netherlands, Belgium and Luxembourg. It sells its own products and also acts as a distributor for third parties. The main focus is on products in
the fields of dermatology, allergy, ophthalmology and CNS. The companys sales are growing and amount to approximately EUR 10 million. With an EBITDA margin of approx. 20%, the company is highly profitable. The reason for the sale is a lack of succession within the family of the owner. If you are interested, we would be pleased to provide you with detailed information.
<p><a style='text-decoration:none;color:blue;font-size:8pt' href='http://www.licensing4pharma.com/newsletter_details.php?url=MTEwZQ==&amp;uid=YmM5NzE=&amp;z=15'><img src='http://www.licensing4pharma.com/images/button_more_blue.gif' width=41 height=24 border=0></a><span style='color:#cccccc;'>&nbsp;|&nbsp;</span><a style='font-size:8pt' href='http://www.licensing4pharma.com/pmcfiles/email_campaign.php?oid=MTEwZQ==&lang=en'><img src='http://www.licensing4pharma.com/images/button_blue_confidential.gif' width=150 height=24 border=0></a></p><hr style='border-top: 1px solid #CCCCCC; height: 1px;'><table border='0' style='font-family:Verdana;'><tr><td><img src='http://www.licensing4pharma.com/images/button_download.gif' width='22' height='23' border='0'></td><td><p style='font-size:8pt;'><a href='http://www.licensing4pharma.com/pmcfiles/download/Unternehmen_en_.pdf'>Download the list of company sales - click here</a></p></td></tr>
<tr><td><img src='http://www.licensing4pharma.com/images/button_search.gif' width='22' height='23' border='0'></td><td><p style='font-size:8pt;'><a href='http://www.licensing4pharma.com/index.php?option=com_wrapper&view=wrapper&Itemid=112&lang=en'>Search the database for specific company sales - click here</a></p></td></tr>
<tr><td><img src='http://www.licensing4pharma.com/images/button_sell.gif' width='22' height='23' border='0'></td><td><p style='font-size:8pt;'><a href='http://www.licensing4pharma.com/index.php?option=com_wrapper&view=wrapper&Itemid=88&lang=en'>Mandate us with the sale of a company or business unit - click here</a></p></td></tr></table>
<p><hr style="height:5px;color:#ccc;background-color:#ccc;border:0px;"></p>
<p>&nbsp;</p>
                <h3><a style="color:blue;" href="http://www.licensing4pharma.com/index.php?option=com_wrapper&view=wrapper&Itemid=91&lang=en" target="_parent" title="switch to Brand Sales, Portfolio Divestments &amp; Partnering Opportunities List View">II. Brand Sales, Portfolio Divestments &amp; Partnering Opportunities</a></h3>
				        <h4 style='color:#000;'>Licenses to Drug for treatment of Genital Warts</h4><p style='text-align:left;font-size:10pt'>Currently, licenses can be acquired worldwide for a drug for the treatment of condyloma acuminata. Condylomata acuminata, also known as genital warts or condylomas for short, is a viral disease caused by the human papilloma virus (HPV). Genital warts are small, soft pink warts that are most commonly found on the labia, penile shaft and foreskin, but can also be found around the rectum or in the oral cavity. In principle, the pathogens are transmitted by contact infection or smear infection. Thus, it is theoretically possible that HP viruses can be transmitted in almost all skin-to-skin contacts, but the main cause of infection is unprotected sexual intercourse. From a global perspective, the number of new infections with genital warts is continuously increasing. There are various hypotheses about the cause of this development. One of them is that the
small injuries caused by intimate shaving increase the risk of genital warts and more and more people shave in the intimate area. Nevertheless, the main risk factors remain: unprotected sexual intercourse, especially if it is performed with several people and at a young age; factors that weaken the body s immune defenses, such as stress, smoking, immunosuppressive drugs, etc. About 1% to 2% of the sexually active population have visible genital warts. In addition, about 5 to 10 % of the population have subclinical HPV-associated lesions in the anogenital area that are not visible to the naked eye and are usually undiagnosed. Antibodies against HPV can be found in the blood of approximately 60% of the population, which indicates a previous infection. The risk of contracting HPV infection in the course of a lifetime is therefore estimated to be between 75% and 80%. Due to its high infectivity and spread, HPV infection is an almost inevitable consequence of sexual contact. Five years
after the start of sexual activity, about 70% of all women have become infected with at least one anogenital HPV type. Between 64 and 70 % of the male relationship partners of women who suffer from cervical HPV disease in turn have HPV-associated lesions on the penis, as several studies show. Medical treatment of the disease is therefore urgently indicated. We will be happy to provide you with more information on the drug upon request.

There are currently approvals for France, all of Eastern Europe and Mexico available. For other regions (Asia, Africa, Australia, Middle East, South and Latin America) dossiers for local registration are available.</p>
<p><a style='text-decoration:none;color:blue;font-size:8pt' href='http://www.licensing4pharma.com/newsletter_details.php?url=MTEwNQ==&amp;lang=eng&amp;uid=YmM5NzE=&amp;z=15'><img src='http://www.licensing4pharma.com/images/button_more_blue.gif' width=41 height=24 border=0></a><span style='color:#cccccc;'>&nbsp;|&nbsp;</span><a style='font-size:8pt' href='http://www.licensing4pharma.com/pmcfiles/email_campaign.php?oid=MTEwNQ==&lang=en'><img src='http://www.licensing4pharma.com/images/button_blue_confidential.gif' width=150 height=24 border=0></a></p><hr style='border-top: 1px solid #CCCCCC; height: 1px;'><h4 style='color:#000;'>Brand to treat Depressions / Egypt</h4><p style='text-align:left;font-size:10pt'>The branded drug put up for sale is an established, widely used, ethical drug for the treatment of depressive disorders. The product is a preferred prescription by physicians in Egypt. Sales of the product are in the range of EUR 5-10 million and growing. If you are interested to
analyze a potential acquisition of the brand, please contact us.</p>
<p><a style='text-decoration:none;color:blue;font-size:8pt' href='http://www.licensing4pharma.com/newsletter_details.php?url=MTEwYw==&amp;lang=eng&amp;uid=YmM5NzE=&amp;z=15'><img src='http://www.licensing4pharma.com/images/button_more_blue.gif' width=41 height=24 border=0></a><span style='color:#cccccc;'>&nbsp;|&nbsp;</span><a style='font-size:8pt' href='http://www.licensing4pharma.com/pmcfiles/email_campaign.php?oid=MTEwYw==&lang=en'><img src='http://www.licensing4pharma.com/images/button_blue_confidential.gif' width=150 height=24 border=0></a></p><hr style='border-top: 1px solid #CCCCCC; height: 1px;'><h4 style='color:#000;'>Brand to treat COPD</h4><p style='text-align:left;font-size:10pt'>At present a prescription brand name drug is being sold, which is used therapeutically for the treatment of chronic obstructive pulmonary diseases. The rights to the product can be acquired worldwide. Further information is available upon request.</p>
<p><a style='text-decoration:none;color:blue;font-size:8pt' href='http://www.licensing4pharma.com/newsletter_details.php?url=MTBmZQ==&amp;lang=eng&amp;uid=YmM5NzE=&amp;z=15'><img src='http://www.licensing4pharma.com/images/button_more_blue.gif' width=41 height=24 border=0></a><span style='color:#cccccc;'>&nbsp;|&nbsp;</span><a style='font-size:8pt' href='http://www.licensing4pharma.com/pmcfiles/email_campaign.php?oid=MTBmZQ==&lang=en'><img src='http://www.licensing4pharma.com/images/button_blue_confidential.gif' width=150 height=24 border=0></a></p><hr style='border-top: 1px solid #CCCCCC; height: 1px;'><h4 style='color:#000;'>Rx-Brand to treat Hypertension</h4><p style='text-align:left;font-size:10pt'>Currently, a branded prescription drug is on sale, which is used therapeutically for the treatment of arterial hypertension. The rights to the product can be acquired in Europe. Further information is available upon request.</p>
<p><a style='text-decoration:none;color:blue;font-size:8pt' href='http://www.licensing4pharma.com/newsletter_details.php?url=MTBmZg==&amp;lang=eng&amp;uid=YmM5NzE=&amp;z=15'><img src='http://www.licensing4pharma.com/images/button_more_blue.gif' width=41 height=24 border=0></a><span style='color:#cccccc;'>&nbsp;|&nbsp;</span><a style='font-size:8pt' href='http://www.licensing4pharma.com/pmcfiles/email_campaign.php?oid=MTBmZg==&lang=en'><img src='http://www.licensing4pharma.com/images/button_blue_confidential.gif' width=150 height=24 border=0></a></p><hr style='border-top: 1px solid #CCCCCC; height: 1px;'><h4 style='color:#000;'>Brand to treat Pulmonary Diseases</h4><p style='text-align:left;font-size:10pt'>Currently, three branded drugs are being sold, which are used therapeutically for the treatment of specific pulmonary diseases. The rights to the products can be acquired in Europe. Further information is available upon request.</p>
<p><a style='text-decoration:none;color:blue;font-size:8pt' href='http://www.licensing4pharma.com/newsletter_details.php?url=MTEwMA==&amp;lang=eng&amp;uid=YmM5NzE=&amp;z=15'><img src='http://www.licensing4pharma.com/images/button_more_blue.gif' width=41 height=24 border=0></a><span style='color:#cccccc;'>&nbsp;|&nbsp;</span><a style='font-size:8pt' href='http://www.licensing4pharma.com/pmcfiles/email_campaign.php?oid=MTEwMA==&lang=en'><img src='http://www.licensing4pharma.com/images/button_blue_confidential.gif' width=150 height=24 border=0></a></p><hr style='border-top: 1px solid #CCCCCC; height: 1px;'><h4 style='color:#000;'>Patented Branded Vaccine against Viral Infections</h4><p style='text-align:left;font-size:10pt'>Currently, a vaccine that is successfully used against severe viral infections is being sold globally. The patent-protected branded vaccine is widely used and shows a continuous sales growth in the 3-digit million EUR range. The brand is sold due to a strategic
reorientation of the originator company.</p>
<p><a style='text-decoration:none;color:blue;font-size:8pt' href='http://www.licensing4pharma.com/newsletter_details.php?url=MTEwMQ==&amp;lang=eng&amp;uid=YmM5NzE=&amp;z=15'><img src='http://www.licensing4pharma.com/images/button_more_blue.gif' width=41 height=24 border=0></a><span style='color:#cccccc;'>&nbsp;|&nbsp;</span><a style='font-size:8pt' href='http://www.licensing4pharma.com/pmcfiles/email_campaign.php?oid=MTEwMQ==&lang=en'><img src='http://www.licensing4pharma.com/images/button_blue_confidential.gif' width=150 height=24 border=0></a></p><hr style='border-top: 1px solid #CCCCCC; height: 1px;'><h4 style='color:#000;'>Brand to treat chronic inflammatory respiratory Diseases</h4><p style='text-align:left;font-size:10pt'>Currently, a branded drug is being sold in Europe, which isused therapeutically for the treatment of chronic inflammatory respiratory diseases. Further information is available upon request.</p>
<p><a style='text-decoration:none;color:blue;font-size:8pt' href='http://www.licensing4pharma.com/newsletter_details.php?url=MTEwMw==&amp;lang=eng&amp;uid=YmM5NzE=&amp;z=15'><img src='http://www.licensing4pharma.com/images/button_more_blue.gif' width=41 height=24 border=0></a><span style='color:#cccccc;'>&nbsp;|&nbsp;</span><a style='font-size:8pt' href='http://www.licensing4pharma.com/pmcfiles/email_campaign.php?oid=MTEwMw==&lang=en'><img src='http://www.licensing4pharma.com/images/button_blue_confidential.gif' width=150 height=24 border=0></a></p><hr style='border-top: 1px solid #CCCCCC; height: 1px;'><h4 style='color:#000;'>Mono- and Combination Drug to treat pulmonary Diseases</h4><p style='text-align:left;font-size:10pt'>Currently, a branded mono- and combination drug is being sold in Europe, which is used therapeutically for the treatment of pulmonary diseases. Further information is available upon request.</p>
<p><a style='text-decoration:none;color:blue;font-size:8pt' href='http://www.licensing4pharma.com/newsletter_details.php?url=MTEwMg==&amp;lang=eng&amp;uid=YmM5NzE=&amp;z=15'><img src='http://www.licensing4pharma.com/images/button_more_blue.gif' width=41 height=24 border=0></a><span style='color:#cccccc;'>&nbsp;|&nbsp;</span><a style='font-size:8pt' href='http://www.licensing4pharma.com/pmcfiles/email_campaign.php?oid=MTEwMg==&lang=en'><img src='http://www.licensing4pharma.com/images/button_blue_confidential.gif' width=150 height=24 border=0></a></p><hr style='border-top: 1px solid #CCCCCC; height: 1px;'><h4 style='color:#000;'>Rx-Eye Care Brand to treat Eye Infections</h4><p style='text-align:left;font-size:10pt'>The branded product, which is sold globally, is a prescription drug for the treatment of infectious eye diseases. The main markets are the USA, Japan, Europe and Asia. The turnover of the product is < 100 million EUR. If you are interested to learn more about the product,
please contact us. We will then provide you with further information.</p>
<p><a style='text-decoration:none;color:blue;font-size:8pt' href='http://www.licensing4pharma.com/newsletter_details.php?url=MTExMg==&amp;lang=eng&amp;uid=YmM5NzE=&amp;z=15'><img src='http://www.licensing4pharma.com/images/button_more_blue.gif' width=41 height=24 border=0></a><span style='color:#cccccc;'>&nbsp;|&nbsp;</span><a style='font-size:8pt' href='http://www.licensing4pharma.com/pmcfiles/email_campaign.php?oid=MTExMg==&lang=en'><img src='http://www.licensing4pharma.com/images/button_blue_confidential.gif' width=150 height=24 border=0></a></p><hr style='border-top: 1px solid #CCCCCC; height: 1px;'><h4 style='color:#000;'>Brand to treat Depressions / Brazil</h4><p style='text-align:left;font-size:10pt'>The branded drug put up for sale is an established, widely used, ethical drug for the treatment of depressive disorders. The product is a preferred prescription by physicians in Brazil. Sales of the product are in the range of EUR 5-10 million and growing. If you are interested
to analyze a potential acquisition of the brand, please contact us.</p>
<p><a style='text-decoration:none;color:blue;font-size:8pt' href='http://www.licensing4pharma.com/newsletter_details.php?url=MTEwZA==&amp;lang=eng&amp;uid=YmM5NzE=&amp;z=15'><img src='http://www.licensing4pharma.com/images/button_more_blue.gif' width=41 height=24 border=0></a><span style='color:#cccccc;'>&nbsp;|&nbsp;</span><a style='font-size:8pt' href='http://www.licensing4pharma.com/pmcfiles/email_campaign.php?oid=MTEwZA==&lang=en'><img src='http://www.licensing4pharma.com/images/button_blue_confidential.gif' width=150 height=24 border=0></a></p><hr style='border-top: 1px solid #CCCCCC; height: 1px;'><h4 style='color:#000;'>Rx-Brand to treat Hypertonia in Brazil</h4><p style='text-align:left;font-size:10pt'>The product marketed in Brazil is an established branded drug for the treatment of arterial hypertension, which achieved sales of approximately 5 million USD in 2020 and is now being put up for sale. Further information we provide you on request.</p>
<p><a style='text-decoration:none;color:blue;font-size:8pt' href='http://www.licensing4pharma.com/newsletter_details.php?url=ZTIw&amp;lang=eng&amp;uid=YmM5NzE=&amp;z=15'><img src='http://www.licensing4pharma.com/images/button_more_blue.gif' width=41 height=24 border=0></a><span style='color:#cccccc;'>&nbsp;|&nbsp;</span><a style='font-size:8pt' href='http://www.licensing4pharma.com/pmcfiles/email_campaign.php?oid=ZTIw&lang=en'><img src='http://www.licensing4pharma.com/images/button_blue_confidential.gif' width=150 height=24 border=0></a></p><hr style='border-top: 1px solid #CCCCCC; height: 1px;'><h4 style='color:#000;'>Rx-Brand to treat Depression for sale in Brazil </h4><p style='text-align:left;font-size:10pt'>Currently, a branded antidepressant is put up for sale in Brazil. It is an established tricyclic antidepressant for the treatment of endogenous depression. The product still achieved sales of approximately USD 5 million and is now available for sale. For further information
please contact us.</p>
<p><a style='text-decoration:none;color:blue;font-size:8pt' href='http://www.licensing4pharma.com/newsletter_details.php?url=ZTIx&amp;lang=eng&amp;uid=YmM5NzE=&amp;z=15'><img src='http://www.licensing4pharma.com/images/button_more_blue.gif' width=41 height=24 border=0></a><span style='color:#cccccc;'>&nbsp;|&nbsp;</span><a style='font-size:8pt' href='http://www.licensing4pharma.com/pmcfiles/email_campaign.php?oid=ZTIx&lang=en'><img src='http://www.licensing4pharma.com/images/button_blue_confidential.gif' width=150 height=24 border=0></a></p><hr style='border-top: 1px solid #CCCCCC; height: 1px;'><h4 style='color:#000;'>Brand in Gynecology for sale / Brazil</h4><p style='text-align:left;font-size:10pt'>Currently, a drug is being sold in Brazil, which is used to treat breast diseases in woman. The product recently achieved sales in Brazil of <5 million USD. For further information please contact us.</p>
<p><a style='text-decoration:none;color:blue;font-size:8pt' href='http://www.licensing4pharma.com/newsletter_details.php?url=ZTI4&amp;lang=eng&amp;uid=YmM5NzE=&amp;z=15'><img src='http://www.licensing4pharma.com/images/button_more_blue.gif' width=41 height=24 border=0></a><span style='color:#cccccc;'>&nbsp;|&nbsp;</span><a style='font-size:8pt' href='http://www.licensing4pharma.com/pmcfiles/email_campaign.php?oid=ZTI4&lang=en'><img src='http://www.licensing4pharma.com/images/button_blue_confidential.gif' width=150 height=24 border=0></a></p><hr style='border-top: 1px solid #CCCCCC; height: 1px;'><h4 style='color:#000;'>New Pain Killer to treat chronic wounds</h4><p style='text-align:left;font-size:10pt'>Currently, the worldwide rights (ex USA) to a new, patent-protected drug can be acquired, which achieves analgesia lasting up to 4 days after a single application in chronic wounds. The development product was submitted to the FDA for approval after completion of the clinical studies
in the USA. Further information is available upon request.</p>
<p><a style='text-decoration:none;color:blue;font-size:8pt' href='http://www.licensing4pharma.com/newsletter_details.php?url=ZWEz&amp;lang=eng&amp;uid=YmM5NzE=&amp;z=15'><img src='http://www.licensing4pharma.com/images/button_more_blue.gif' width=41 height=24 border=0></a><span style='color:#cccccc;'>&nbsp;|&nbsp;</span><a style='font-size:8pt' href='http://www.licensing4pharma.com/pmcfiles/email_campaign.php?oid=ZWEz&lang=en'><img src='http://www.licensing4pharma.com/images/button_blue_confidential.gif' width=150 height=24 border=0></a></p><hr style='border-top: 1px solid #CCCCCC; height: 1px;'><h4 style='color:#000;'>R&D Project at Phase III - Drug to treat chronic Blepharitis</h4><p style='text-align:left;font-size:10pt'>For an R&D project at the beginning of Phase III clinical trials, partners or buyers are sought to take the project through to regulatory approval and to professionally roll out the product globally or in specific regions. The product is a patent-protected drug
for the treatment of chronic blepharitis, an inflammation of the eyelid margins that can be acute or chronic. Symptoms include itching and burning of the eyelid margins with redness and edema. Phase II studies for the product have been successfully completed. Now, two Phase III studies in the USA and Europe are pending, in which a total of approximately 1000 patients must be included. The capital expenditure for the production scale up to manufacture the investigational product and conduct the two clinical trials is approximately USD 16.5 million. Approximately 10 million people in the U.S. suffer from chronic blepharitis; none of the available therapeutics (antibiotics, corticoids) are suitable for long-term therapy. Therefore, the investigational product qualifies as a new gold standard for the therapy of this disease. Conservatively estimated sales expectations for the product are approximately USD 2 billion in the first 5 years. If you are interested in a collaboration or in
acquiring the IP rights to the project, please contact us.</p>
<p><a style='text-decoration:none;color:blue;font-size:8pt' href='http://www.licensing4pharma.com/newsletter_details.php?url=MTEwZg==&amp;lang=eng&amp;uid=YmM5NzE=&amp;z=15'><img src='http://www.licensing4pharma.com/images/button_more_blue.gif' width=41 height=24 border=0></a><span style='color:#cccccc;'>&nbsp;|&nbsp;</span><a style='font-size:8pt' href='http://www.licensing4pharma.com/pmcfiles/email_campaign.php?oid=MTEwZg==&lang=en'><img src='http://www.licensing4pharma.com/images/button_blue_confidential.gif' width=150 height=24 border=0></a></p><hr style='border-top: 1px solid #CCCCCC; height: 1px;'><table border='0' style='font-family:Verdana;font-size:8pt;'><tr><td><img src='http://www.licensing4pharma.com/images/button_download.gif' width='22' height='23' border='0'></td><td><a href='http://www.licensing4pharma.com/pmcfiles/download/Produkte_en_.pdf'>Download the list of brand sales and partnering projects - click here</a></p></td></tr>
<tr><td><img src='http://www.licensing4pharma.com/images/button_search.gif' width='22' height='23' border='0'></td><td><a href='http://www.licensing4pharma.com/index.php?option=com_wrapper&view=wrapper&Itemid=91&lang=en'>Search the database for brand sales and partnering projects  - click here</a></p></td></tr>
<tr><td><img src='http://www.licensing4pharma.com/images/button_sell.gif' width='22' height='23' border='0'></td><td><a href='http://www.licensing4pharma.com/index.php?option=com_wrapper&view=wrapper&Itemid=92&lang=en'>Mandate us with the sale or out-licensing of brands, products and development projects - click here</a></p></td></tr></table>
<p><hr style="height:5px;color:#ccc;background-color:#ccc;border:0px;"></p>

<p><hr style="height:5px;color:#ccc;background-color:#ccc;border:0px;"></p>
<p>&nbsp;</p>
<h2>Investors seeking to buy</h2>
               <p><img src="http://www.licensing4pharma.com/images/stories/fruit/pmc_mail_logo20.jpg" border="0" width="800" height="210" /></p>
              <h3><a style="color:blue;" href="http://www.licensing4pharma.com/index.php?option=com_wrapper&view=wrapper&Itemid=89&lang=en" target="_parent" title="switch to Companies sought to buy View">III. Companies sought to buy</a></h3>
			 		    <h4 style='color:#000;'>We are seeking to acquire Assets in Germany and Austria to buy with a focus on Dermatology, Gynecology or Urology  (Rx) and OTC</h4><p style='text-align:left;font-size:10pt'>We are a pharmaceutical manufacturing and distribution company in Germany employing more than 350 managers (of which about 120 employees are sales force representatives visiting doctors and pharmacies) and have sales in the high 2-digit million Euro range.</p>
<p><a style='text-decoration:none;color:blue;font-size:8pt' href='http://www.licensing4pharma.com/newsletter_details.php?url2=MmI=&lang=en&amp;uid=YmM5NzE=&amp;z=15'><img src='http://www.licensing4pharma.com/images/button_more_blue.gif' width=41 height=24 border=0></a><span style='color:#cccccc;'>&nbsp;|&nbsp;</span><a style='font-size:8pt' href='http://www.licensing4pharma.com/pmcfiles/email_campaign_ks.php?oid=MmI=&lang=en'><img src='http://www.licensing4pharma.com/images/button_make_offer.gif' width=95 height=24 border=0></a></p>
<hr style='border-top: 1px solid #CCCCCC; height: 1px;'><h4 style='color:#000;'>Strategic investor seeks acquisition opportunities in the area of hospital products/patient care</h4><p style='text-align:left;font-size:10pt'>A global corporation specializing in patient care in clinics, practices and nursing homes which supplies these facilities with high-quality medical products is looking worldwide for acquisition opportunities in the fields of wound and skin care, compression and support therapy, diagnostics, patient care and patient hygiene. Targets include branded products, product portfolios, business units and companies. The target turnover is between 20-200 million EUR. If you may offer any attractive assets, please contact us.</p>
<p><a style='text-decoration:none;color:blue;font-size:8pt' href='http://www.licensing4pharma.com/newsletter_details.php?url2=ZWI=&lang=en&amp;uid=YmM5NzE=&amp;z=15'><img src='http://www.licensing4pharma.com/images/button_more_blue.gif' width=41 height=24 border=0></a><span style='color:#cccccc;'>&nbsp;|&nbsp;</span><a style='font-size:8pt' href='http://www.licensing4pharma.com/pmcfiles/email_campaign_ks.php?oid=ZWI=&lang=en'><img src='http://www.licensing4pharma.com/images/button_make_offer.gif' width=95 height=24 border=0></a></p>
<hr style='border-top: 1px solid #CCCCCC; height: 1px;'><h4 style='color:#000;'>Investor is seeking to buy Hospital Business (Drugs and Medicinal Products) in Europe</h4><p style='text-align:left;font-size:10pt'>A financially strong US-American investor is looking to buy a pharmaceutical company specialized on hospital business in Europe to market its own hospital products. The company specializes in the distribution of injectable drugs (e.g. analgesics and anaesthetics, etc.) for hospitals and clinics. The company should ideally have a hospital sales force and an established pharmaceutical and distribution infrastructure to serve at least the big 5 European countries. Turnover of the company should be in the range of approx. EUR 15-30 million. If you are interested, please contact us.</p>
<p><a style='text-decoration:none;color:blue;font-size:8pt' href='http://www.licensing4pharma.com/newsletter_details.php?url2=ZjA=&lang=en&amp;uid=YmM5NzE=&amp;z=15'><img src='http://www.licensing4pharma.com/images/button_more_blue.gif' width=41 height=24 border=0></a><span style='color:#cccccc;'>&nbsp;|&nbsp;</span><a style='font-size:8pt' href='http://www.licensing4pharma.com/pmcfiles/email_campaign_ks.php?oid=ZjA=&lang=en'><img src='http://www.licensing4pharma.com/images/button_make_offer.gif' width=95 height=24 border=0></a></p>
<hr style='border-top: 1px solid #CCCCCC; height: 1px;'><table border='0' style='font-family:Verdana;font-size:8pt;'>
<tr><td><img src='http://www.licensing4pharma.com/images/button_search.gif' width='22' height='23' border='0'></td><td><a href="http://www.licensing4pharma.com/index.php?option=com_wrapper&view=wrapper&Itemid=89&lang=en">Search the database for companies which clients of us are seeking to buy - click here</a></p></td></tr>
<tr><td><img src='http://www.licensing4pharma.com/images/button_buy.gif' width='22' height='23' border='0'></td><td><a href="mailto:info@licensing4pharma.com?subject=Search%20for%20company%20acquisitions&amp;body=Dear%20Sirs%2C%20%0A%0AWe%20are%20seeking%20to%20acquire%20companies%20with%20the%20characteristics%20as%20described%20below%3A%0A%0ATarget%20Company%20%0A%0AKey%20therapeutic%20areas%20%0A%0ASales%20volume%20%0A%0ACountries%0A%0A%E2%80%A6%0A%0APlease%20provide%20us%20with%20a%20proposal%20for%20the%20conduct%20of%20a%20targeted%20search%20for%20potential%20acquisition%20opportunities%20in%20the%20above%20described%20field.%0A">Mandate us with the targeted search for company acquisitions - click here</a></p></td></tr>
</table>
<p><hr style="height:5px;color:#ccc;background-color:#ccc;border:0px;"></p>
<p>&nbsp;</p>
              <h3><a style="color:blue;" href="http://www.licensing4pharma.com/index.php?option=com_wrapper&view=wrapper&Itemid=93&lang=en" target="_parent" title="switch to Products sought to buy View">IV. Brands &amp; Licenses sought to buy</a></h3>
			  
			    <h4 style='color:#000;'>OTC Brands sought to acquire / Germany, Austria, Switzerland</h4><p style='text-align:left;font-size:10pt'>On behalf of a major media company we are looking to buy in the German-speaking countries (Germany, Austria, Swizerland) pharmacy-only branded drugs, herbal medicines, homeopathics and medical devices with revenues (and without sales). Even company acquisitions are of interest. Investments up to 500 million euros are possible.</p>
<p><a style='text-decoration:none;color:blue;font-size:8pt' href='http://www.licensing4pharma.com/newsletter_details.php?url2=ZDU=&lang=en&amp;uid=YmM5NzE=&amp;z=15'><img src='http://www.licensing4pharma.com/images/button_more_blue.gif' width=41 height=24 border=0></a><span style='color:#cccccc;'>&nbsp;|&nbsp;</span><a style='font-size:8pt' href='http://www.licensing4pharma.com/pmcfiles/email_campaign_ks.php?oid=ZDU=&lang=en'><img src='http://www.licensing4pharma.com/images/button_make_offer.gif' width=95 height=24 border=0></a></p><hr style='border-top: 1px solid #CCCCCC; height: 1px;'><h4 style='color:#000;'>Strategic Investor is seeking to buy Branded Drugs in Africa</h4><p style='text-align:left;font-size:10pt'>A financially strong pharmaceutical distribution company is looking to purchase branded pharmaceuticals (Rx and OTC) and product portfolios with existing sales of up to approx. EUR 120 million. Products with sales in the low 1-digit million range are also of interest. The
therapeutic areas and indications are not defined. If you want to sell brands in Africa, please contact us. </p>
<p><a style='text-decoration:none;color:blue;font-size:8pt' href='http://www.licensing4pharma.com/newsletter_details.php?url2=ZjE=&lang=en&amp;uid=YmM5NzE=&amp;z=15'><img src='http://www.licensing4pharma.com/images/button_more_blue.gif' width=41 height=24 border=0></a><span style='color:#cccccc;'>&nbsp;|&nbsp;</span><a style='font-size:8pt' href='http://www.licensing4pharma.com/pmcfiles/email_campaign_ks.php?oid=ZjE=&lang=en'><img src='http://www.licensing4pharma.com/images/button_make_offer.gif' width=95 height=24 border=0></a></p><hr style='border-top: 1px solid #CCCCCC; height: 1px;'><table border='0' style='font-family:Verdana;font-size:8pt;'>
<tr><td><img src='http://www.licensing4pharma.com/images/button_search.gif' width='22' height='23' border='0'></td><td><a href="http://www.licensing4pharma.com/index.php?option=com_wrapper&view=wrapper&Itemid=93&lang=en">Search the database for products and partnering projects which clients of us are seeking to buy or licensing in - click here</a></p></td></tr>
<tr><td><img src='http://www.licensing4pharma.com/images/button_buy.gif' width='22' height='23' border='0'></td><td><a href="mailto:info@licensing4pharma.com?subject=Search%20for%20brand%20acquisitions%20and%20partnering%20projects&amp;body=Dear%20Sirs%2C%20%0A%0AWe%20are%20seeking%20to%20acquire%20brands%2C%20products%20or%20development%20projects%20with%20the%20characteristics%20as%20described%20below%3A%0A%0ATarget%20Products%20%0A%0ATherapeutic%20Area%20%0A%0ASales%20volume%20%0A%0ACountries%0A%0A%E2%80%A6%0A%0APlease%20provide%20us%20with%20a%20proposal%20for%20the%20conduct%20of%20a%20targeted%20search%20for%20potential%20acquisition%20%26%20partnering%20opportunities%20in%20the%20above%20described%20field.%0A%0A%0A">Mandate us with the targeted search for brand acquisitions and partnering projects - click here</a></p></td></tr>
</table>
<p><hr style="height:5px;color:#ccc;background-color:#ccc;border:0px;"></p>
<p>&nbsp;</p>

<p style="font-size:10pt;">
		Contact us if we can assist you with your purchase, sales and partnering projects.</p>

<p style="font-size:10pt;">
		Mit bestem Dank und freundlichen Gr&uuml;&szlig;en aus Zug<br />
		Many thanks and best regards from Zug in Switzerland</p>
	<p style="font-size:10pt;">
		<br />
		Dr. M. Raber<br />
		Managing Director/Gesch&auml;ftsf&uuml;hrer</p>

<table border="0" cellpadding="0" cellspacing="1" style="font-family: Arial, Helvetica, sans-serif">
		<tbody>
			<tr>
				<td colspan="2" style="font-size:8pt;"><strong>PMC Pharma Management Consultants GmbH</strong><br />
		Alisbachweg 22 C / CH-6315 Oberaegeri<br />
		Switzerland</td>
			</tr>
			<tr>
				<td style="font-size:8pt;">
					Phone:</td>
				<td style="font-size:8pt;">
					+41 (0) 41 720 20 22</td>
			</tr>

Mobile:</td>
				<td style="font-size:8pt;">
					+41 (0) 79 358 21 86</td>
			</tr>
			<tr>
				<td style="font-size:8pt;">
					Web:</td>

<td style="font-size:8pt;">
					<a href="http://www.licensing4pharma.com/redirect.php?url=YmM5NzE=">www.licensing<span style="color:#990000"><strong>4</strong></span>pharma.com</a></td>
			</tr>
			<tr>
				<td style="font-size:8pt;">
					Email:</td>
				<td style="font-size:8pt;">

<a href="mailto:info@licensing4pharma.com">info@licensing<span style="color:#990000"><strong>4</strong></span>pharma.com</a></td>
			</tr>
		</tbody>
	</table>
	<p><img src="http://www.licensing4pharma.com/pmcfiles/pmc_line.jpg" width="600" height="6" border="0"></p>
<table border='0' style='font-family:Verdana;font-size:8pt;'>	
<tr><td><img src="http://www.licensing4pharma.com/images/button_contract.gif" width="23" height="22" border="0"></td><td><p style='color:#666666'><a href="http://www.licensing4pharma.com/plaintext.php?url=YmM5NzE=">If you prefer to receive this newsletter as a plaintext (text only) version, please click here!</a></p></td></tr>
<tr><td><img src="http://www.licensing4pharma.com/images/button_pen.gif" width="23" height="22" border="0"></td><td><p style='color:#666666'><a href="http://www.licensing4pharma.com/index.php?option=com_wrapper&view=wrapper&Itemid=20&lang=en">Complete / Change your profile, please click here</a></p></td></tr>
<tr><td><img src="http://www.licensing4pharma.com/images/button_register.gif" width="23" height="22" border="0"></td><td><p style='color:#666666'><a href="http://www.licensing4pharma.com/index.php?option=com_wrapper&view=wrapper&Itemid=106&lang=en">Subscribe to this newsletter by registering once, please click here</a></p></td></tr>
<tr><td><img src="http://www.licensing4pharma.com/images/button_unsubscribe.gif" width="23" height="22" border="0"></td><td><p style='color:#666666'><a href="http://www.licensing4pharma.com/unsubscribe.php?url=YmM5NzE=">To unsubscribe to this newsletter, please click here</a></p></td></tr>
</table>
<p>&nbsp;
	</p>
<p style="font-size:8.0pt;color:#666666">
	Diese E-mail einschlie&szlig;lich ihrer Anh&auml;nge ist vertraulich. Wir bitten, eine fehlgeleitete e-mail unverz&uuml;glich zu l&ouml;schen und uns eine Nachricht zukommen zu lassen. Wir haben die e-mail beim Ausgang auf Viren gepr&uuml;ft - wir raten jedoch wegen der Gefahr auf den &Uuml;bertragungswegen zu einer Vireneingangskontrolle. Eine Haftung f&uuml;r Virenbefall schliessen wir aus.</p>
<p style="font-size:8.0pt;color:#666666">
	Este e-mail as&iacute; como cualquier anexo adjunto son confidenciales. Si usted no es el receptor intencionado de este e-mail por favor, borre sus contenidos de inmediato y h&aacute;ganoslo saber. Este e-mail ha sido comprobado con un antivirus previo env&iacute;o; a&uacute;n as&iacute;&not;, es recomendable revisarlo de nuevo por una posible contaminaci&oacute;n durante la transmisi&oacute;n. Denegamos cualquier responsabilidad por contaminaci&oacute;n de virus.</p>
<p style="font-size:8.0pt;color:#666666">
	This e-mail and any attachments are confidential. If you are not the intended recipient of this e-mail, please immediately delete its contents and notify us. This e-mail was checked for virus contamination before being sent - nevertheless, it is advisable to check for any contamination occurring during transmission. We cannot accept any liability for virus contamination.</p>

</div>
<p>&nbsp;
	</p>

</body>
</html>

--b2_cc63032ee40edd6fa81a3cd738d16e60--
--b1_cc63032ee40edd6fa81a3cd738d16e60
Content-Type: image/png; name="banner_nli_english.png"
Content-Transfer-Encoding: base64
Content-ID: <b384c0cc6a789604b770c2c5a9101600>
Content-Disposition: inline; filename="banner_nli_english.png"

iVBORw0KGgoAAAANSUhEUgAAAyAAAABaCAIAAADPQ6UFAAAAGXRFWHRTb2Z0d2FyZQBBZG9iZSBJ
bWFnZVJlYWR5ccllPAAAA2ZpVFh0WE1MOmNvbS5hZG9iZS54bXAAAAAAADw/eHBhY2tldCBiZWdp
bj0i77u/IiBpZD0iVzVNME1wQ2VoaUh6cmVTek5UY3prYzlkIj8+IDx4OnhtcG1ldGEgeG1sbnM6
eD0iYWRvYmU6bnM6bWV0YS8iIHg6eG1wdGs9IkFkb2JlIFhNUCBDb3JlIDUuMy1jMDExIDY2LjE0
NTY2MSwgMjAxMi8wMi8wNi0xNDo1NjoyNyAgICAgICAgIj4gPHJkZjpSREYgeG1sbnM6cmRmPSJo
dHRwOi8vd3d3LnczLm9yZy8xOTk5LzAyLzIyLXJkZi1zeW50YXgtbnMjIj4gPHJkZjpEZXNjcmlw
dGlvbiByZGY6YWJvdXQ9IiIgeG1sbnM6eG1wTU09Imh0dHA6Ly9ucy5hZG9iZS5jb20veGFwLzEu
MC9tbS8iIHhtbG5zOnN0UmVmPSJodHRwOi8vbnMuYWRvYmUuY29tL3hhcC8xLjAvc1R5cGUvUmVz
b3VyY2VSZWYjIiB4bWxuczp4bXA9Imh0dHA6Ly9ucy5hZG9iZS5jb20veGFwLzEuMC8iIHhtcE1N
Ok9yaWdpbmFsRG9jdW1lbnRJRD0ieG1wLmRpZDoyMjlEQjk2OTdDNjVFNzExOTZGREYzODhFMzk1
MkMyNCIgeG1wTU06RG9jdW1lbnRJRD0ieG1wLmRpZDo3OTM5NjVBRDZCOUMxMUU3OTcwNjhCRThF
QTY1OTc2NCIgeG1wTU06SW5zdGFuY2VJRD0ieG1wLmlpZDo3OTM5NjVBQzZCOUMxMUU3OTcwNjhC
RThFQTY1OTc2NCIgeG1wOkNyZWF0b3JUb29sPSJBZG9iZSBQaG90b3Nob3AgQ1M2IChXaW5kb3dz
KSI+IDx4bXBNTTpEZXJpdmVkRnJvbSBzdFJlZjppbnN0YW5jZUlEPSJ4bXAuaWlkOjIyOURCOTY5
N0M2NUU3MTE5NkZERjM4OEUzOTUyQzI0IiBzdFJlZjpkb2N1bWVudElEPSJ4bXAuZGlkOjIyOURC
OTY5N0M2NUU3MTE5NkZERjM4OEUzOTUyQzI0Ii8+IDwvcmRmOkRlc2NyaXB0aW9uPiA8L3JkZjpS
REY+IDwveDp4bXBtZXRhPiA8P3hwYWNrZXQgZW5kPSJyIj8+PlzIuQAAKl5JREFUeNrsnXtQVFme
53MaSR4C8kjkpSTPROQlDxVEVEpb0FarynGsmiqtqZrooSs6Yid2e2Nrt2Mjtrfnn47piZ3Z6ImY
7bKromrKqh7Lqbaq0bDA0fItqLwhRUgEEuUlyUNBSJKyY7+ZPzh1vZlcMnmVyO8TGRkn7z2P3zn3
Zp5v/s6556woer9CxTAMwzAMw8wfP+AmYBiGYRiGYYHFMAzDMAzDAothGIZhGIYFFsMwDMMwDMMC
i2EYhmEYhgUWwzAMwzAMCyyGYRiGYRiGBRbDMAzDMAwLLIZhGIZhmKWPW+b+Im4FhmGYpULJmeJv
Ll2Oi4329PSiI6e+ONnb1RkVE7tAJXY/6Pi3E5/7eXsGBa/W11Z/VXwapbu5uX344YcToyNrtFEL
Xd+6utrE9UlL4upI20ocnJiwLHJbSUsUl0zcMMziwB4shmGYpUTWpk14f2A00kdDo940MJSelcUt
wzDPFSu4CRiGYZYQmtWhqYkJVXX1uvVJ7u7qe/fu4eMq/8CFKzFsTWRR0fc21lG47wBf9Lm0VVJa
Ol7cOCywGIZhmBlITEmpa2xqbzH4+Pp2dPXkbN2Kg4+GBqorKppb2xHWxUSlZ2WR6jp+/JPgAH/q
ersfdJw+W5Kflxuf+N2Im6FRf/Hq9YOvHIB0Mz3sOfVV8cYNqembsiltcoIuNDzcPtV06Gurr9+8
nbt5I96h/LLztqPQ2poa2ImzIpOJCUtleRlqYZWMgf4HDx0m8+xjlpwp7hscev3110+cOLE2LHTH
rt04OPpk5NPPfq+QvxSqIIVhmExtzFh9hKcrovpW+e2aOmrwTTlbvFf62OeMEnVT45uotbQWVER8
lBa1sG9AaOixMTNyTk5Nrbh1C6V7eXnuyt8BvTtdpaitjh59y/6KvHb4EO4HipCRmoIjOEUNKI1G
dRkYGnoyZpblw7DAYhiGecFBT4musV6v9/b0JPcV1NXnJ79A10iupkvnzxWfPgNR4u6unjG3gKAg
vA/290Nh4B29eFtHB1QF1AY6eKirWVjY19dHlkAJnb94CRoCCs/Y2lJ6/huIQkiEC6Ulo2Yz9frQ
ClAeExaLw5iUISqCU4Z2I2Ii3Ndr1Tra6Ojp8pca028yHXnzDagf6CFoCETQxsQ5X/3pikBuDU3N
QrhcufiN1IEETQYBhKsD6QObpbWArNz0ZAT2IA6KQC0cNiD0Damo+909B/bv27nSB+KsrLz84KHI
GSulAEpUq9W4OqSowiIikBAFIUzakVQ42oG/aHOE52AxDMMsPVIzMp+MmTu6ehJTUvCxtbkZ75ty
ttDZ5NRU9KPtLQZnsoKwQG/a2dmJMEQbFIBpYAiqgtSGTKw4CQygQJO+AZbAWqseiolDhsa2NsgU
WJ6SlEQ+NnTqUB4OY0rzhBBBhK77HQi3tbZqAv1h24ypQHbedvItrY2KwrtlfNyl6jssAhFu19Ql
J+ioCrGxsagRZC7labGJRehdqWtK1MKqn2wCEflQLaZrwNVhYVazw0JRCpoIAdhGck25UgrAfvLA
rdFq8T4yPEwVhyV0HPbAcv6KsQeLYRhmOYLONTjAv081RB38uK1/dVdP+qsogG7eWT2UoGtoaoZo
QP9duGevod0IBQDNgR59duYJS8iwTz/7vTg19OhRkEaDgI+vrzSJw5jSCOj4IQK6OzvD10be7+7J
zsp0JpXKNprWbzLRcKTDZlGuvsMiSOVAY9EQITE6MkIBGt1LWLfOvmWoFhCIVr9RuzEjNUW5AYGn
h4cs4EylXAJiHbeTfYkMCyyGYZhljYetR5ywWGhMcMLW3arVaieTB2o0YzV1TfoG9P2QbhAWAyYT
RMy23C3zYtg777wtHaw0trbYawKHMWVER0ZCCYVFREC+RERqnUlFo2wbN6QWFRXRQKqr1XdYBNSY
ytGMru4HVgcbxF+9Xl9WXl64J1A2MQukJCWVV1TCMNSC3Eiu4kylXGXUbBbhrt5e/k7NHR4iZBiG
WfLE6HR4v1V2gz421NVBK0TFxatsA0wdXT2mh9Yxqaa7dx0mD18b6eXlCe2SEG9NEhERgTC6/+CQ
0DkaRgNYleVl9FFfWw1BgOJgXmVVFY2p0RwshzHtc4NVSKiLiZIOkCmnAjSTrLG+fhbVd1gESocN
VXX1VBzeUQtpnjt37XoyZr5y8Rv74ui6QGMhh7k8/qlcKZfISE0xDQxRFWjhD/5OzR32YH2f0HxJ
/NAU7tlLcxXJ20zPs3D7SP8skn8ev0c7du3Gb/GF0hL0Gc481jRjZFnm83JNVdM8zfTcNinfY0sd
9NP79xbW1tQcO3aMLit+Vcjjsilni9lsPvVVMTREcoLOYXKa39Pc2h5im/QTEBQEeUHunDkahp+y
gl0vQRIJw2h1CZgHOUiuFxzEl8VhTPvcYBW6/8yMDIX8ZWpG19lJs7anHY9TrP50ReRu3wHVRVVA
5jJvH64IjuDX4NL5c4gpK46mukfHxMyuVZ2plEskpaUPP3588ep1mpgfGR7aN8gaa678WdH7FdwK
c4Ee6532x2Xq8WOH4ItHz1Tj26uNiXshBZaoFEE1naMaEG2u3LyyCzRd5MUUWKIsgO5QOrlVPHQ9
uyZigcUwS4jyq5cN7cbndh2EU1+ctPZEM/26MsrwEOH3Cf19Qcc/dz/88vqzHhCIP1gq21SG+Y28
mJSVl4uHt5cEkID4S0CzZ5QPMgyj/K+vrrGJJuk/P99uMcSpr602DQw9bz+YSxEeIpwrmtWhYo1j
4a2h5UlmTKuNiSsqinux24fW65tfz5x1fMHpxZ1diryoP7IDQ8139EtlhWXhYJMOajg8yDCMAseP
fzI2Zs7dvPG5mkKwOizswvnz9HXGf/7nfIYDCyyGYWbg+s3ba7TaBd3khGGY54rnc1gQv0I8IMgC
a4kxMWFpbzGIDQ1U02yzoODxMjTq6/WTz3R4eXlmZ2WK5NLpPrQgiuxvBy3Iq3p2P4Tyq5dp6RR6
6vjR0EBrc7OYJoWYcQkJws9EkzrF7CX7iTunvjhJth185cDXpefwz2zGPcukmSSsW1dWXk45yOYe
Ce8I1dphDrSjRcmZYtrCgpZUllYcfxOj4+KlkWfM3JlaSy8K5ZyQlOzSdGC0s6HdiOYqu3ZNwcGG
S1xZVUUF0Y4ZuDTiqWzxiLjY40LM66IqUAT7S2y/+CFhetjTUFdH8wJR/cyMDLoi4ioD2y33Dc35
tT9I8aWbeEgbR9zwiNl45w6uGj/PwTDMiwrPwVpggWWxSNUVwEd0M04mh3RAfNGNoT/GRxyUzd0p
r6gUy81JoRXtrB1eu/E74WILo9uDuoIQQVctnYSOfE59VTyLKTWkrlxKcr+7BzJI2knTk+SkAkW7
Ua0V8omNjaXAw+5uCvR0dVHA4RozLmXuEKm6UtkGQEu+PutSDh4eHrvydyAAkSF7ulsA2WRtk6mC
oHtwadBEEJG0i8X9+/cnW3IqMNDfr7I9MU4fA4OCoA6LT5+RXWKHxeFmQP6krlS2EUyUPp1tM960
0sb5w6lTsjv2yvUbpIkZhmHYg8XMBvxxl3p0yHuELke4UhRA30adkHA5kAMAB9tbDLIBcuG8kZGS
lITeDjIC3Sf0Fm19pbKt7II+7/zFS+TF2VOwm1wj6IwRAf3f62sjndnFTEBborrUOCiIHBjCsUHb
gdEMUHyMDA/dWVAIM2SPIsqwLipj69H7TaZ425GGpmZKjjah9QClThqXMneI1JdO3hrIEeTskjMG
lwNXFsZAH9OSiTI7ySkl3fIWl76hrm7HrlB6xptuD1xH2gUW7QmllZSWPjQwQJcVRUAr0xWnfGiH
XQf/BKZuBuGlI68YbEPzor72DznS/mWyg+KmpSuLxoe6oj1bpHdscID/ztcLXbrBGIZhWGAx8q6L
dgSzWCzCeTBq2+lTOSHtjQUys3MmRUx6BkmBe/fuSburjNSU6ebx2Hru6+TbQHdLHg5NoD/pGOp6
kZyUATKhXdZx3NTb49IeZLDN1ZZBX07lQu1RvWhXrEGbkSBtwwbqg0XFHYI4yKq5td3QbszMtqBt
qV7CsyXF1cwV5O+kaK6opMCTkRHNatcySc3IpIHCuqpK2jxE0DvljaOVacTx+91W+WKL3ETOKtqd
g1bxgbjB/UbNCBGmkqzlTZmsDgtzOD6Iy02NhkyabcOLQgSjPZ2fJYY7kwKytUuE9pU1PsMwDAss
ZjYor5KlzMDQkBAQsoB0TwOV4oYYkHHkJqmqq09KS8e7amrBgidT22ZJk4uwqztbzWN/SfpAJd1Y
babMo2NioAxIF4rktFzy3DOXAcFR8vXZeVnpGFcnOysT0gcXKDXxmVPTbd1KMkg47R52d9OVSli3
DtqLWoBGDEmxQSVv3JBKCpI0lsOFrxQu94Qrd4LszhSYn62Ou5rVFcMwLLCYOXDlyhXyGEHT+Pj6
ond3fsaPt6fnZA83MbW/2NRElkB/f+dtiEuwCix0vbT1lWrSreVYS4nwSh+f76vR1FP7jIqu3eHe
F1LC10462wb6+/v6+lS2cVWHymkWmcto0jeQusrPy1XZFn2etYYG8YlJ9+7d6+jqkU2NEnbK1iMV
ojAy3Lr/Ce6o3ocPvbw8NSGT44bWFrAtwSz0Zfqm7ISk5M4OY3lFJW4AKNGIRr1sUFLcDPZ7q7km
GaduWuUd5RiGYV54eJL7wkI9cXhIiHUjiJBQMYDiDGKEq6G6ShaIiIhwPh/aXEI1NZgl9vCCPTRX
WrqdFrm4rB22bfCOEqIWFKHNNta50AQGBVGgtqaGNGV1xQz7DaAvh6JS2aZ70zRtbXT0rDNXrvWj
x48pDhQMLuv99vY51jdn61ZlO8U0MusCgFPPAaxdu9ZqW0cHZBakFVqAXFZNBgNUFOQX6RtjawuE
Na44TFXYuFcztdQtbgBRBKWVxRQuQIcHySqVZOM2GF9+9TL/FDAMs9xgD9bCQnOD6hqbyD9BPber
vo3bNXXSSUK0b5dLZoip7irbWJIQJbvyd5w+W4Ljss3Y9xTsliZEQOy35WoLSKeQn/qquGDXSzMu
Wx+2JpLcM3h99NHHThYERSXmfdP87llnrlxrqFtcU8gvSu7SNXXIKv/A3M0baUq71E66eWCn2F1H
ZZs8TgHaNI0UPEmr1ZIjQuio7GZxqaZcmDKFmp+XSzeJ1CFHXjqRucq2dhdeNKvd/mB0XDwUHmwQ
9zwx3cIQDMMwLyrswVpYNuVsQTcp+ipXNx8o3HcAqUQHTwvszmLnuKi4eMpEpjwQRodNvh9i44bU
1w4fEk/DQcnhCIURTQivhWZnQaEoFw24f2/hjElQF9FQyrufzpi5cq1lZ3Oys+deX936JHuhhgst
vfp0C4lnI3CNxCkSOmL5BpVkfQr/wMmdgqTX1+EDFqgXmkIWOWDKkYbMoZ/spaHsIHLe//Ir0Ivi
CN20/FPAMMxygzd7XhaIpTLnOMOGYRiGYRhnYA/WsuBW2Q0KRDt6sI5hGIZhmPmF52C94ByTrGkk
HWBiGIZhGIYFFjMnvLw8t+Vuke70xzAMwzAMCyxmlsy49TLDMAzDMPMOz8FiGIZhGIZhgcUwDMMw
DMMCi2EYhlk09LXVx44dc7gHVMmZ4uPHP1FOjjinvjg5YymGRv0xG90POha/jk4aOe8NyDAssBiG
YRjb3uRniuddA5ke9ly8en3jhtSioqLpdk1YEhVZBC6dPwfF5uqp+QI6GO3GX4TvBZ7kzjAM80KR
lJYu1hN+NDjQ0dWTtsGF5IX7DswYh/ZK9/H1XbRKySrijJHPAxMTlubW9uDgYJdOzSMubYDLzC+8
kjvDMMxS4tL5c/e7e44efUtl809cvHqdtoY0Peyh7T5Hhoev37z92uFDD4xG6R6X77zz9oXSkr7B
oYzUFDqui4my33qr5Ewx4iB/KICPPvqYNvuiPdTz83LjE5P0tdWybFW27b3FjquZGRm0KAxllZyg
u11Th7QWiwUJczdvrKqrHxszI+fk1NSKW7egnLy8PHfl7yBnGFWKMqfNJ+xLpIpQI8BOhdJFZVMT
E+z3xDS2tlRWVdEOnrAnd/sOd3c1FQeD6/V6nEKeOdnZZNt0ZZVfvYyDMAzJqd1QnDY6+vTZElHW
/r2FwtvX/aBDdsrbx6e6ooLaOTI8NGfr1lX+gRRt44bUto6OJ2Nm1PfR0EDZtWu06SqKQKF0UVSS
jV9RkU05W9zVaul2q2hJ3fokqfEHDx3mb9OC4pa5nx/jZxiGWTJMjJsN99q0ayO8V/rU19aMms2+
3l5hEWs6O4y9fX05ubn9fX33O7uSk9avjYoJDwluNrSg/96R/5Kbm1tLc1P/4FDkmog9P9r3g6cT
9Y1NmoBV/gGB0vwRB3mmpaX96U9Pa2pqEH/79m1527b3dXfW6hsT1yVErNVStujadxfuQbZ//PIP
T58+3X/gQHZOzp8mLJBHiODrt4qKi9ZGorig4NV9vT0wzMtD/fKrB/28PStr69uNxl0/3LVp06aG
hobe3p7E9VahYLjb+MOCAmQFC8srq2EhBIR9RchIxFcuPS4mGkZ6rvhBRU2dfWXRaDqdDnni1K3K
anfVn9CSZKd6hduefQdSU1MeGNsbGu+uX5+oUNMHaHxTf3r6BsShdgsJ1iSmpCE5whA3aAFEE+Ui
LDt1v63Vz88PpqKFK6qrH9zvQGuMPH6EWlss44V79mZlWbf4PHvmtPuKFQcPHUKjtRiaqXnRtlBX
DU3Nf37wldzcrXfv6I3tbQmJ6zMzM3HVVvn6vPaXb6wODaurvF3dcOfgKwdwNc0jw5rVq2Etf6EW
Dp6DxTAMs5SgHbgH+/tHn4w0t7bHR2nbOqwzkzo7O9eGhbq7q5WTe3l50gDi2iira2pkeFg5vi4m
inZ/j42NVdmG6uydQKaBocT162mjCGSOIpru3pUVJ0hOte6VTjuUw+BV/oGwGQFkMjFhHXnMzttO
WZGFlvFxBfNmLJ28O7T9uX1lEZ+8StqYOER+9PixzE7YhoqPjZlNvT3KZc0R2EmmInO0xpMxsziV
kpREJQoD6CqThSrbBLXbNXXJCTo0Jl2pjq6e6Sbp487Be/qm7BlvFWaO8BwshmGYpQTkjibQH3JK
7eGBQFyCdZwIXez97p7srEzn83FXO9W/enp4KEcgAaR+Njez2exMuSJzaSmGRn2/yUQjWdb8bfO9
5qt0Gd0POgb6+8X4ozShsFNtsw1mzLEsZXAF21oMTQYDjVeqbMORypUVFlJMaCwaIpzMcGSE9NZ3
kjE9Awry4tXreImBRYYFFsMwDDNJdGRkQ1PzKj8/BKC3rH4UfcPYmDkiUrv4xgj98Yws8/ScXW40
AYueT3w0NPD5yS8WrnTkf/psiS4m6sibb3iv9JEtYDExlSfJmpU+Pg4F36xrKqPk67Penp402Ytm
dE2rKacMGBqY9FGRL4rmqylJanf1jl27d9im8aGRA4KCyDfJLBA8RMgwDLPECA0Ph5yCxkJAZRto
Q1gT6D/dbu4zjgPOBW1MHIpuvHNn9MmIyraIFGwTo1ezriDeG+vrZ6zIXEonCRUcHIx2g7AbG3vG
F9VQZ/UGIdt6vT4yPBRaRKGsII0G7+0tBrw339HLCurr65vOBnGKxgShriD7DO1Gh5Gj4uIhpmHA
xIQFLwToOOyHTKyqq6dhQWsOjd/Z0Dc4JMQrWb7Qjy4yxPLyYL2ZE5GXFIJAa8/wr88Y+PIzi4Yu
ZOVPC+I81W7vn2up7nj8wte3IDn41ey1CJRWdX1Z1bPMW2PeQTeMjpYCeI+IiGhubU9O0DmMia6X
RoXocb+FoHDP3ltlNz797Pcq2xNw+/cWzto1Ag2h6+w8fbYEFcxITXGmIrMuHdE2bki9fvM2PdtI
TSpY5ed37Ngx1dRDecplxScmdXZ2knnISmTi7q7GR+TffOyY9ClC+1PbcreUnv8GJaI4KGZ6nFAG
kuzK31FWXv7RRx9D6kVHRtLjhCB3+47K8jJy+KEiyI2Op23YgMZEtihLrVaT5YiQn5fL7quFZhkt
0/CfdsckRfpTeB4F1q9eTw7wmRwIt+9LpIXKzqIH2pEcQmm7B8Yu1PdcMwwqFJQe6feT3XHTFSTl
vX3xMaHTrk/zZfn90oY+vvUXmVczQgsyrH/KKwz9H1w2LnOBtdxag2EWAmNrCzQZLdLBrfEcslyG
CPGPmYQOpMy7H1QtkPsqNSpA+tHPc0XsNEIHHQy6H6HMwgK9jmyPhoRSyDwzOmC6gpaEvIDsQ6e7
bL9p+s5hs+UpApVtg04mCV/lgXaDgkfgBbtks2gNhmFUtgW3aJjv0dBA4507mkB/VlfPLctliDA6
2JsCde0L8oOO3sJT7QadBCXX3PuEDubEBeAgnXIoxQZHLL/66q6Ph9t7L69DnPURvtMNl0CrJWv9
pytIhpCP6Jj/118kfe9+AuGuqG0fWrbfNFys//xJrUtJjuRFKngil/Qlm0VrMAwDPDw8aJhPZVto
dFv+S9wmLLCeF0Zt/5vnna6BUeoLkyJ8he7RhfuSioIecphqcGT8sflbvCZtG7fatjU+4Mj2aATe
+7ROnEpd60sq7XJDL/V80oIYhmGY5UD6pmy8uB1YYD0vSKdJvZq9Fi8xLwRqZkuCRvgJrup7L94x
dT2yPpQr3D+tPcOGrmHIGuWZW90DYxBSqVEBlLOf5woalKxrH7QXWBfqe6CiUO6Pt2sjgrwhnqDD
Ltwx4dST8UkJ6OPhJgRWum180Gx5isy3J4cgvijIVWRVRqX+o66XPGcKVRYuDdjwRVkHSUBpg6RH
+v0wNYSyRV0uNfTSTC/7xqdJYDIz7GfqCKGp7xj653OtdFDMaSP1qQtZuW2dJis+iM4i5rW7JuEF
/O2PM8iYn59okNXO4XVUaBnpjKI1Gm/YIAyWzqWTJpEhcqDqSzO0nrW1LUw9eaMDyYWpBIX/7t/1
uDNxau+GUFFlabuJpn7/XMtf7YjGTfLuB1VU8emS2Dcgmnq6S6ZcWdzwhzdHUFb4LrR0K01dl7WG
9NLcaDL9KDOCiuD5ggzDLF2W9TINb+ZEkMoRR/KSQt57eR16HWm08EBv6v+UocFHGrxT2cYHSY60
m0btI18zDKIvQQAdEpLQWCHJqdV+kxNuSOdJtdo9W5LbBpO0IFdZF+4nrTLCP9kdJ5vlI6syZI34
iG6bdI9MmiATkS16R2vHnBGqIPJkLR8f7mvfRGgWBKTz2ChcYehHWyGTn+1PEOIAoJVgxqynDTnT
MlC34qkFuoWkc+koifJcOhnIULQt8oEwwuWeLjKMwf0prTLSvrcvXhaN1NWMSXDqpwVxsgZU/r5M
V1nY/PNXvisFNyc9rusquPFwY0jlnUuNyTAMwx6sReXnJxpk/5jJ40J9AP5t/+5CK9QMxUHP9MrG
cKmHA0ec+Sd9896gdPCOxgdJDMmAMHonP1o8P4jeCOF3d0X/9nwbdMPaIG/6Ky/ik1YD1bYZwUbT
aJ7t48YY/1mMEn5w2SjmY8ESaBQENsc+4w+TVhkNJZ4PoIb68XattFdG53ooJ1LqGaLlMCAdLtwx
ofGF90vkiRwo7T+ebrK2VchK1MXe1FvNJiSEMdBS0Ft4J91Q2TYoCoWE/ddLbdUdj8WT/3sywsta
BoXzb35bRtgsvYWET+gXBxNxNX+YGuL80gNjlqe//uPdkfGn/2VvPNLC/tjV3kj+7gdV4mlQ8l2p
bM+HkrPzn7824IjQqbBEWmKDcUhU5Ehe5HRJIOWpPcl+NOlfbYuk74v9JVOu7M71GrqfabYfsqLq
uHoJxMIN4h6L0njzOg4Mw7DAWkrgh5sCF+p7qPdCR5Kt06BXQPcj9SJAWDgzToFMxCghhAWJkjud
Dtb3I3UFZfAvpS3oqtHnQSugUPRJUDA0mV06uTgtalJ81N0fJtcO4qMrStYGqMo6Z1F3lBjsa3XM
iKcRg3yf8dNIq2zfUCdvdkoFlpgfhirQqJzoLENXeTgUOmOWb0VTQEWhuT5zVBGhWbUab9Raa7ME
WgE9Lvp7KhQSljpgtCTCEAHW8dO1vsprXsy6ZVCEELXrI3yFT0jq8AsP9Ha+RFSfWlUMJQsXpgzc
k6S3cPNIBxDtVQgukDNJ+obHhf0q25N9YijWHuXKCgckFY2LToPgrrY/NDpVBBqa7jFZ+zMMw7DA
et4RP9xizpO04/fxcLM/OCPUR+KFP/TkXCEpIOvC6b++6KohBR4+tvxsfwISUi8o1TeijwS/PvLM
8sTIR+a6cAblVbLsq2zfUDLNtNJj2rtopYfjrdpPV/fGhfmR6446bIerJUF56DuGIFU3xmugwPBO
ikSqQkYll0+EFUyaY8tIi/NSr5jODbMQd6yPh7PZiguknAQ33rpwP9IxtqugtD6ccmUDfDxkRUu/
VgzDMCywlhFCQ0hFgOhFaDaxq3leuGOiP/ebdBrVNOODDoHSgsIQs8h/d+E7RwJpNQW/gksCqyA5
OGZqGlP/8DgMlok2ZxpK1jJPxicjXNX3fuacRw3d8C9PNUIdwn4aeELd9Z3D9iOe1+5afYHoxV/N
CKW+/Oa9QWmh3pLLJ8IPH4+7eu3m0jKfXm6bncPMJUamJAv0N1pvXpJ8cNl4tqZnc2wAPTmBFkA7
O3x4Qrmy5qmHc/F/gDSWcHwyDMMsT5bvJHcxeLczJZQGBNHF0hiNvmOWa/+ga6G5U+Sjcjg+2Ppw
cs77xniNcG6hV0MPJ+KE2BQM6RgxVvWPp5ve/aCKXn/373qRiUsWek85V67cNaEfFbO7FDBOTdIX
DXUkL1IagQYuZTWyTmizm+Su8VWL+m6ND4A0hCCDoFEoHXFoqju1D5p3ckDt/uRKlSiUJvtbJ3LF
f+c4VNkGE+laUIR8Rak6x5YRovPNnIj5mpc9NqVaYlZ7090FnaSyTSEXbYuyUKLCDamQhK4R2hP1
/dr2MKM94pIpV1Y8M3h4cwTduvQfY4FAob/9ccb/fSuNrqzsIyqFj784mKjwuADDMAx7sBYK9MFX
9b15SSHoe6S+CvTKf7jZOetsDV3D5AgR3bwM9GfkrPJUu4mtb4SbAQchCMRxiCrSfLBK6t0R870Q
36VRQvFII83gJgmizDXDIPpUGvqkhjI/u5YYenGHNSqd6rP1ncMFtqlZaG28viy/H+TrgfjSOTqy
CkoRU90RvtFkEoXSahE4TnUR/OulNmlCUVmz4hJos2sZWtZBjO3KtPsceWAapZl8qCZeUNXFFZ3U
wtKJUNLnIexRTiKbUKWachDaX7LShj6Fyl68Y4K6xbXIig+Szs9bIGhXAxRHD5TIPpK2g530uAD/
yjMMwx6sxeazsk70HPQXX2iCX311V6yPMAtoLSuV4vjgl1U9n15uk/aL+o4hWPLLU40oXXh0YFjS
1MziBqN8UEYsSS/dQscZWYmCRP4fXWxzJtU/nTUIrx7MFgpGViNpS6IWQrKgzxOFEne7HkvlDjW7
QpNSZLxLB6cQfv9ci9TdiEIhSUWfCqtEYyKavdlzb5lfnzHAeFldeudw/8haVebeg5GooLTKuBzK
i60rJGnrG5VdMsSkm9/+kilXFqn+pbRF3NLIqnQal9i8QBvswBK9Td7JPtIsPVTt3sNR/olnGOb7
Yhlt9szMF2LbaecnXc0FsQrl4hTHMAzDMHPnB9wEzIy8mROxNX7ST4bA4S2Tc7Au3jEtQuliytfi
FMcwDMMwc4cngTIzExHknZcUIlvWqLSqq2uexsKmQ7qq1iIUxzAMwzAssJjFo7Z9SLpAVIWhv7Jt
cNGmD5stT7+u6uI96RiGYZglBM/BYhiGYRiGmWd4DhbDMAzDMAwLLIZhGIZhmOcbt8z9RdwKDMMw
S5SJCcuHH344MTqyRhs199y6H3T8x7nSq9eue674werQMPsI+trqr4pPx8VGe3p6lZwpLrt5My0t
TZbDv5343M/bMyh4NV8dKXm6wP/55+vd/0x1t2tEIVq4v8dPd8e+tT0qK9r/Ej86vZThSe4MwzBL
DIiY8xcvvf766+7u6lkkv3T+XHBwcFJauv0pZBsc4F9UtOB/vBVsWOYc3aYND/T+5cmGriF+bnpp
w0OEDMMwS4yB/v6xMfPs0k5MWJpb26c7hWz9V62ai21hayKhz+ITk2ZnA+Nl2xaM1dULAHuwGIZh
lhIlZ4o7unoQ+OijjyPDQ3cWFCJsHh+/dP4cqZb8vFzSN8bWlsqqKtOAdWckXUxU7vYdpt6e02dL
8PH6zdt47d9bCD1E2XY/6KBTdY1NeOGUxWKRJXfGYUb5kA362mqUkrt5Y1VdPaQbWevQBqmpqYkJ
mdk50rIgyE6cOLE2LHTHrt105PjxT+KjtNl52x8NDVRXVFDFYWR6VtYq/0Ac/PzkFyiXPGRkxmuH
D+EUWq9vcCg5QXe7pk40FFGQEpyfEhrgYy23pKrry4puBP4mX5tl20W+tWf4+BUjdI+f54q3t2uT
tNZ9Qs2Wp2crO0vr+3DwH95Ko92iYkJ9/88f7zb3Pnk1K6xwaq9PHKGAxlf9vw8lhgV6I+0XNzqu
Ng8IAygTCr9flHmlofezGw+kVumNQx9fNj42f0uRhRmDI5b/8fv6vy2Ixcf/9kktIlBWiP+b0nv2
MflLtDiwB4thGGYpUbjvAKQDAu+88zbCdBAKI2HduqKiIoiYi1evjz6xzvIZGR7Oyc7GwYJdLyFC
Q3UVpAxS4RRywHGhrlQ2zxOdgr6hU/bJZ2dwX1/f0aNvQUhBFzq0wdCoLz3/TUpSEj4eefONrt7e
C6Ul0hwgtiCnYAPVCxoOck0bHU1CCkeKbCBQfPoM1JiyPUir9vCQudnC/T0O5kQOjoz/5FilEENQ
V8naAHzEQS+1W9GuGBwMXeWBdxzBC/GRCmkpPqTVjbsmHIe6Qlqoq1NlHfj46aU2H083ihMb5nfs
fOsvTzYg/KOsCKlhEEaI3D0wCu2FANQVJBryv9lszRNJwoO8f7YvniIjgI9kGyJARU1X39dyIqCu
3i81IOa97scKMRkWWAzDMMwz6GKiSC3Fxsbi/dGg1S+SlJZOB7UxcV5eno8eu7Y48ByTC5JTU0nA
IZPehw/tI9Tr9ZpAf5I73it9oLQgxUwPe6RxIKesWq3XetDY1ob4yLC1uRkfN+VsEQVBPLW3GJTt
gRkKc7+glqybnVd0I5AVr2kwDuKjyrbecligty5kJT7+pvQeRaZ900lykZeLPFKUVm8cKq23rpCM
g1XGydaDGOoaGre+BkYDfNTKcmezTjM4YiFfGpIgLWzI0PoVpAQjgI9kGyKQW0sBbfBKvP/uonHG
mMx8wUqWYRhmyePp4WF/sPtBx0B///Wbt+mj2ezatK05Jhe4q2cYWHwyZg4O8JcdnLA844iCnIKo
amtthdoztBszUlNwcHx8XJo/BSwWyyyMhHw5VdaxNzPiF4eTaTTQx8PaP0In0RAhEbLKKr/e3LJm
jcZb7G+x0mOyJx0bf0oBSts/rDSPSkRW0oJqt8EReSYoztuWv+mxU/O0Pi/rDPT1KMwIx0sMfTIs
sBiGYZjZ8Gho4PTZEl1M1JE33/Be6XP8+CeLmdwlVnp5jtqpN3tZlpKUVF5RaWjUj42Z12i1OOJh
k5WQYjRhizSZWq2enRml9X145ekCD22JPLpNC42FgzQRShrtbwtiY8N8LzX0/n1xs3SWlZSRcauX
yNvDbY4tM2Z56qmWd9NPxr/1HndzPv/H5m9hKgL//YAO1hr7ngh3GrOg8BAhwzDM0pRQgwMKZ0lt
BAcHQx6RKJGe7eubYXNP5eTzgrABysk0MIRSEB59MlKv10PYaVaHyuJHxVmnH0Fj4ewq/0CEY3Q6
vN8qu0ERGurqNIH+iIazXl6eTQbDxIQFGSIwozG6kJVQSwjUTu2y2jU03tozvEmnwSlpBC+brLnQ
YJ3Ynhbl7zA3SpsVrylICVbZVsDK0PrNooluNpsCfNRUbri/x2adBtlCHpUZBgdHLPkpoWQbIsCY
+/2jCO9Mtpa4P+O71sNZmiX2wDTK35rFhD1YDMMwS4zouHiIhlNfFYunCO2BQNm4IZWe1MvdvBGC
g467u6vxEQebjx2TPkXoZPJ5QWYDzb6Ccrp49ToCKDd9U7bDVPFR2rrGpuiYGDoCIYXktTU1x44d
U9kmohXu2UverF35O85fvEQPWoaHhNDziQr0PBr/650ackfRECEC/+9c69vbtf/15XWqqQcGEfjy
Zudf74z5h7fSugdGO/tHwwK9HWb498XNf5OvPZgTaZs7b/nN2ebY1S53uDSctyM5hAyrMJh+d9Fq
2GPzt8jw6LZJ22AwYuKlC/elocArDb3SfH5xOJmqUFLVxe6rRYM3e2YYhmGWBuVXLxvajUePvsVN
wTz/8BAhwzAMswQwPeypa2zKzsrkpmCWBDxEyDAMwzzvHD/+ydiYOXfzRuU14hmGBRbDMAzDOAsP
CzJLDh4iZBiGYRiGYYHFMAzDMAzDAothGIZhGIYFFsMwDMMwDMMCi2EYhmEYhgUWwzAMwzDMi8r/
F2AArIp+tYpTyNEAAAAASUVORK5CYII=

--b1_cc63032ee40edd6fa81a3cd738d16e60
Content-Type: image/png; name="Banner_MAs_en.png"
Content-Transfer-Encoding: base64
Content-ID: <c56650c3e96de7a73a7a0970d9969b10>
Content-Disposition: inline; filename="Banner_MAs_en.png"
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--b1_cc63032ee40edd6fa81a3cd738d16e60--